Subsequent immunohistochemistry analysis on these CDX tumors show positivity for commonly used markers for SCLC diagnosis: CD56, synaptophysin and chromogranin A, demonstrating the stability of the patient’s neuroendocrine tumor lineage (Fig. 1D). This evidence concerns the gene NCAM1 and small cell lung carcinoma.